Bas ter Braak
Bas ter Braak is postdoctoral researcher at the Division of Drug Discovery & Safety.
Bas ter Braak obtained both his BSc and MSc degrees in Biotechnology at Wageningen University. During his studies he completed three graduation Master projects (at Wageningen University, at Lisbon Technical University in Portugal and at Emory University in the United States). Directly after completing his studies in 2010 he started working as a PhD student at the Leiden Academic Center for Drug Research at Leiden University, on the project “Carcinogenicity of insulin analogues.” Bas defended his thesis on June 18th 2015. Since then he is employed as post-doctoral researcher at Leiden University on a project in which cell signalling reporter stem cell models are established for the mechanistic understanding of liver disease.
We are currently developing a new models for the mechanistic understanding of Drug Induced Liver Injury (DILI) using multiple fluorescent tagged human induced pluripotent stem cells (hiPSC) using clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system. With this system we can tag the endogenous stress-gene. Once we have developed these hiPSC-reporter cells we can differentiate these cells towards hepatocyte-like cells and use these for High Throughput drug Screens (HTS). We anticipate that our cellular stress response reporters in combination with High Content Imaging (HCI) may play a key role in future safety assessment of chemicals.
No relevant ancillary activities